Abstract:Following the publication of the above article, an interested reader drew to the authors' attention that the western blots for the PCNA and cyclin D1 bands appeared to be strikingly similar. The authors were able to re‑examine their original data, and recognize how the error was made with respect to the compilation of this figure (they were also able to demonstrate to the Editorial Office how the error occurred). The revised version of Fig. 3, now incorporating the correct data for the PCNA bands in Fig. 3A, is shown on the next page. The authors can confirm that the errors associated with this figure did not have a significant impact on either the results or the conclusions reported in this study, and all the authors agree with the publication of this Corrigendum. The authors are grateful to the Editor of <i>International Journal of Molecular Medicine</i> for allowing them the opportunity to publish this Corrigendum; furthermore, they apologize to the readership of the Journal for any inconvenience caused. [International Journal of Molecular Medicine 46: 1135‑1145, 2020; DOI: 10.3892/ijmm.2020.4667].

Correction: Corrigendum: Patient-specific Hepatocyte-Like Cells Derived from Induced Pluripotent Stem Cells Model Pazopanib-Mediated Hepatotoxicity

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Corrigendum To: "pkcα/zfp64/csf1 Axis Resets the Tumor Microenvironment and Fuels Anti-Pd1 Resistance in Hepatocellular Carcinoma" [J Hepatol 77 (2022) 163-176].

Correction: Corrigendum: A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation

Correction: Corrigendum: Inhibitory Receptors Bind ANGPTLs and Support Blood Stem Cells and Leukaemia Development

Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Corrigendum to “artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis”

Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes & Diseases 9(2022) 443–455]

Correction: Corrigendum: Autophagy-associated alpha-arrestin signaling is required for conidiogenous cell development in Magnaporthe oryzae

Correction: Corrigendum: Mesenchymal Stem Cells Reversed Morphine Tolerance and Opioid-induced Hyperalgesia

Corrigendum to ‘therapeutic HNF4A Mrna Attenuates Liver Fibrosis in a Preclinical Model’ [J Hepatol (2021) 1420-1433]

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

[Corrigendum] Propofol‐induced HOXA11‐AS promotes proliferation, migration and invasion, but inhibits apoptosis in hepatocellular carcinoma cells by targeting miR‐4458

Corrigendum to "Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients"

[Corrigendum] Omi/HtrA2 pro-apoptotic marker differs in various hepatocellular carcinoma cell lines owing to ped/pea-15 expression level

Corrigendum to “circumventing Intratumoral Heterogeneity to Identify Potential Therapeutic Targets in Hepatocellular Carcinoma” [J Hepatol 67 (2017) 293–301]

Correction: Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Correction: Corrigendum: Epigenomic Reprogramming of Adult Cardiomyocyte-Derived Cardiac Progenitor Cells

Author Correction to ‘FGF4 Protects the Liver from Immune-Mediated Injury by Activating CaMKKβ-PINK1 Signal Pathway to Inhibit Hepatocellular Apoptosis’ [acta Pharmaceutica Sinica B 14(2024)1605-1623]